Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of Bosentan on Nintedanib PK
NCT02667704Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2016
- Primary completion
- Mar 2016
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of nintedanib in idiopathic pulmonary fibrosis (IPF), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of Nintedanib in Plasma Over the Time Interval From 0 to the Last Quantifiable Concentration up to 216 hours and Maximum Measured Concentration of Nintedanib in Plasma up to 216 hours. Started Feb 2016; status: completed.
02
Drugs
nintedanib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02667704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02667704.